Rafferty Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Rafferty Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Buy	+4,405	New	+$212K	﹤0.01%	1099
2026 Q1	–	Sell	-5,065	Closed	-$252K	–	1140
2025 Q4	$252K	Buy	5,065 +385	+8%	+$18.7K	﹤0.01%	1031
2025 Q3	$224K	Buy	+4,680	New	+$188K	﹤0.01%	1055
2024 Q4	–	Sell	-7,570	Closed	-$236K	–	1173
2024 Q3	$236K	Sell	7,570 -43	-0.6%	-$1.34K	﹤0.01%	1072
2024 Q2	$204K	Buy	+7,613	New	+$221K	﹤0.01%	1136
2022 Q1	–	Sell	-6,908	Closed	-$201K	–	1319
2021 Q4	$201K	Sell	6,908 -1,589	-19%	-$48.2K	﹤0.01%	1228
2021 Q3	$227K	Buy	+8,497	New	+$228K	﹤0.01%	1173
2019 Q4	–	Sell	-7,862	Closed	-$216K	–	902
2019 Q3	$216K	Buy	+7,862	New	+$233K	﹤0.01%	773
2018 Q2	–	Sell	-56,529	Closed	-$2.59M	–	699
2018 Q1	$2.59M	Buy	+56,529	New	+$2.36M	0.04%	228

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Rafferty Asset Management's SUPN Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 4,405 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #1099 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in SUPN as recently as Q4 2025.

Rafferty Asset Management first reported a position in SUPN in Q1 2018 and has held it in 9 quarters since. The position peaked at $2.59M in Q1 2018. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Rafferty Asset Management held 4,405 shares of Supernus Pharmaceuticals worth $205K as of Q2 2026.
Supernus Pharmaceuticals was a new Rafferty Asset Management position in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1099 holding.
Rafferty Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and has held it in 9 quarters since.
Rafferty Asset Management's Supernus Pharmaceuticals position peaked at $2.59M in Q1 2018.
335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.